Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development.
Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development.
复制标题
DOI：
10.3390/v16010128
复制
发表时间：
2024-01-16
期刊：
影响因子：
--
通讯作者：
Jung JU
中科院分区：
文献类型：
--
作者：
Kim D;Lai CJ;Cha I;Jung JU
SFTSV是一种新兴的蜱传病毒，引起出血热，病死率（CFR）可高达27%。随着东亚的地方性感染和最近媒介蜱虫传播到美国20多个州，SFTSV疫情已成为全球日益严重的公共卫生问题。然而，目前还没有针对SFTSV的靶向抗病毒治疗或许可疫苗。考虑到年龄依赖性的SFTS发病机制和疾病结局，需要一种复杂的疫苗开发方法来保护老年人免受致命的SFTSV感染。鉴于最近出现的SFTSV，建立动物模型来研究免疫原性和对SFTS症状的保护只是最近才发生的。最新的研究工作应用了多种疫苗开发方法，包括减毒活疫苗、DNA疫苗、全灭活疫苗、病毒载体疫苗、蛋白质亚单位疫苗和mRNA疫苗，以寻求开发安全有效的SFTSV疫苗。本文综述了目前SFTSV疫苗的研究进展，并提出了未来的发展方向，以提高疫苗的安全性和有效性，确保其适合临床应用。
SFTSV is an emerging tick-borne virus causing hemorrhagic fever with a case fatality rate (CFR) that can reach up to 27%. With endemic infection in East Asia and the recent spread of the vector tick to more than 20 states in the United States, the SFTSV outbreak is a globally growing public health concern. However, there is currently no targeted antiviral therapy or licensed vaccine against SFTSV. Considering the age-dependent SFTS pathogenesis and disease outcome, a sophisticated vaccine development approach is required to safeguard the elderly population from lethal SFTSV infection. Given the recent emergence of SFTSV, the establishment of animal models to study immunogenicity and protection from SFTS symptoms has only occurred recently. The latest research efforts have applied diverse vaccine development approaches—including live-attenuated vaccine, DNA vaccine, whole inactivated virus vaccine, viral vector vaccine, protein subunit vaccine, and mRNA vaccine—in the quest to develop a safe and effective vaccine against SFTSV. This review aims to outline the current progress in SFTSV vaccine development and suggest future directions to enhance the safety and efficacy of these vaccines, ensuring their suitability for clinical application.
登录
查看更多内容
影响因子：
3.8
作者：
Chen, Xiao-Ping;Cong, Mei-Li;Zhang, Yong-Zhen
通讯作者：
Zhang, Yong-Zhen
影响因子：
6.4
作者：
Brannan, Jennifer M.;Froude, Jeffery W.;Dye, John M.
通讯作者：
Dye, John M.
影响因子：
3.7
作者：
Ding S;Niu G;Xu X;Li J;Zhang X;Yin H;Zhang N;Jiang X;Wang S;Liang M;Wang X;Yu XJ
通讯作者：
Yu XJ
DOI：
10.1177/2051013615595595
发表时间：
2015-07-01
期刊：
Therapeutic advances in vaccines
影响因子：
--
作者：
Cox, Manon M J;Izikson, Ruvim;Dunkle, Lisa
通讯作者：
Dunkle, Lisa
影响因子：
16.6
作者：
Du, Shouwen;Peng, Ruchao;Xu, Wang;Qu, Xiaoyun;Wang, Yuhang;Wang, Jiamin;Li, Letian;Tian, Mingyao;Guan, Yudong;Wang, Jigang;Wang, Guoqing;Li, Hao;Deng, Lingcong;Shi, Xiaoshuang;Ma, Yidan;Liu, Fengting;Sun, Minhua;Wei, Zhengkai;Jin, Ningyi;Liu, Wei;Qi, Jianxun;Liu, Quan;Liao, Ming;Li, Chang
通讯作者：
Li, Chang